(Press-News.org) Rockville, MD. (October 6, 2025) – The 2025 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship will convene an extraordinary roster of world-renowned scientists, entrepreneurs, investors, and patient advocates on October 24, 2025, at the National Press Club in Washington, D.C.
This is a signature annual gathering where the leaders driving the future of oncology come together under one roof to challenge the status quo, reveal bold ideas, share insights, and spark collaborations that shape what’s next in cancer research and patient care.
World Renowned Leaders, Visionary Topics, Global Impact
This year’s keynote will be delivered by Monica Bertagnolli, M.D., the newly elected President of the National Academy of Sciences and distinguished leader who previously served as Director of the National Institutes of Health and the National Cancer Institute.
Other distinguished speakers and participants are Webster K. Cavenee, Ph.D. (Ludwig Institute for Cancer Research/UC San Diego), a globally acclaimed leader in cancer genetics and tumor biology; Lisa Coussens, Ph.D. (OHSU Knight Cancer Institute), internationally recognized for tumor immunology and former President of American Association for Cancer Research; Ronald DePinho, M.D. (MD Anderson Cancer Center), a leading voice in cancer biology and drug development; Tony Hunter, Ph.D. (Salk Institute), recipient of the 2025 Szent-Györgyi Prize for Progress in Cancer Research. Also in attendance will be Raju Kucherlapati, Ph.D. (Harvard Medical School), a world-renowned geneticist whose work has shaped modern precision medicine; Nathan Lear (AstraZeneca), Head of Advanced Medical Analytics and a leader in applying AI and machine learning to transform clinical trials and patient care; Kornelia Polyak, M.D., Ph.D. (Dana-Farber), breast cancer expert; and Dennis J. Slamon, M.D., Ph.D. (UCLA Health), a pioneer in breast cancer precision medicine and recipient of the 2024 Szent-Györgyi Prize for Progress in Cancer Research.
2025 NFCR Global Summit Programming Highlights
Precision Medicine & AI in Oncology
Cancer’s next frontier will be shaped by artificial intelligence and precision medicine. Sessions will highlight breakthroughs in AI-driven cancer discovery, adaptive therapy, predictive medicine, and early detection, with speakers from AstraZeneca, Cedars-Sinai, Dana-Farber, Harvard, MD Anderson, OHSU, Stanford, UC San Diego, and the University of Maryland.
AIM-HI Oncology Leadership & Entrepreneurship Forum
The future of cancer breakthroughs depends on translating discoveries into therapies. This forum, led by Patty Obermaier (Former VP of Microsoft/Health Tech), will feature emerging oncology companies (ResNovas Therapeutics, Chiara Biosciences, Acurion, and Window Therapeutics) alongside leading investors from Eos BioInnovation, PagsGroup, and others, offering attendees rare access to both the science and business of cancer innovation.
Szent-Györgyi Prize & Evening Ceremony
The capstone of the NFCR Global Summit is the Szent-Györgyi Prize for Progress in Cancer Research, awarded this year to Tony Hunter, Ph.D. for his discovery of tyrosine phosphorylation — a breakthrough that launched the era of targeted cancer therapies and paved the way for more than 50 FDA-approved drugs. The evening will be emceed by Kristen Berset-Harris, cancer survivor and former WUSA-9 host, and will include a “Live from the Press Club” panel with iconic cancer research leaders.
More than a meeting. The NFCR Global Summit is an opportunity to be part of “what’s next” in the fight against cancer.
The NFCR Global Summit is designed to catalyze new collaborations to develop, news to be made, and action plans to be developed, organically generated and mutually stimulated real-time provocative and thoughtful discussions. This event convenes the leading voices shaping cancer research, provides direct access to innovators and investors, and takes place at the National Press Club — a historic venue known as the stage where major developments are announced to the world.
A testimonial from 2024 keynote speaker Dr. Drew Pardoll (Johns Hopkins) captures the essence of the NFCR Global Summit:
“This meeting is very different, which is what makes it so much fun. It’s a mix of outstanding basic research scientists, translational investigators, clinical investigators, and people from the private sector. Bringing these perspectives together fosters brainstorming and real collaboration — while celebrating successes and acknowledging the work still ahead.”
Space is limited (by design). Reserve your tickets now for the 2025 Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship on Friday, October 24, 2025, at the National Press Club in Washington, D.C. All net proceeds support NFCR’s cutting-edge cancer research programs.
Learn more and register at: https://www.nfcr.org/events/global-summit-2025/
For sponsorship inquiries, contact Sponsorship@nfcr.org, or call 1-800-321-CURE (2873). Ask for Brian Wachtel, Executive Director of NFCR.
Press and media are encouraged to attend. Interested outlets should contact Jonathan Larsen, NFCR Chief Marketing Officer, at jlarsen@nfcr.org
About the National Foundation for Cancer Research
The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization co-founded in 1973 by Nobel Laureate Dr. Albert Szent-Györgyi and attorney/business entrepreneur Franklin Salisbury, Sr. NFCR provides scientists in the lab with the critical seed funding they need to make game-changing discoveries in cancer detection, treatments, prevention, and ultimately, a cure for all cancers. NFCR has distinguished itself in the cancer research sector by emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources. With the support of more than 5.7 million individual donors over the last 52 years, NFCR has provided more than $420 million in funding to cancer research, prevention, and public education. NFCR-supported research has led to some of the most significant life-saving discoveries that benefit patients today.
To learn more about the National Foundation for Cancer Research, visit www.NFCR.org
About the AIM-HI Accelerator Fund
The AIM-HI Accelerator Fund (AIM-HI) is a 501(c)(3) nonprofit organization established in 2019 with an initial capacity-building grant from the National Foundation for Cancer Research to accelerate the translation of cancer drug discoveries by investing in seed-stage oncology companies. AIM-HI Accelerator Fund bridges the gap between innovative cancer discoveries and high-impact cancer treatments and technologies, and facilitates an ecosystem for early-stage companies and entrepreneurs.
To learn more about the AIM-HI Accelerator Fund, visit www.AIM-HIAccelerator.org
About the Szent-Györgyi Prize for Progress in Cancer Research
The Szent-Györgyi Prize for Progress in Cancer Research was established in 2006 by the National Foundation for Cancer Research in honor of its co-founder, Albert Szent-Györgyi, M.D., Ph.D., recipient of the 1937 Nobel Prize for Physiology and Medicine. The award recognizes outstanding scientists whose seminal discovery or pioneering body of work has contributed to cancer prevention, diagnosis, or treatment and has had a lasting impact on understanding cancer, holding the promise of improving or saving the lives of cancer patients.
The 2025 Prize is awarded to Tony Hunter, Ph.D., of the Salk Institute for Biological Studies, for his discovery of tyrosine phosphorylation — a groundbreaking finding that transformed cancer biology and led directly to the development of life-saving targeted therapies. You can find the prior winners here: https://www.nfcr.org/szent-gyorgyi-prize-past-winners/
END
AI and the Future of Cancer Research and Cancer Care to headline October 24 gathering of global oncology leaders at the National Press Club: NFCR Global Summit to feature top scientists, entrepreneurs
Event spotlights “what’s next” in cancer breakthroughs, entrepreneurship, and patient care, culminating in honoring Dr. Tony Hunter with the 2025 Szent-Györgyi Prize for Progress in Cancer Research
2025-10-06
ELSE PRESS RELEASES FROM THIS DATE:
FDA clears UCLA heart tissue regeneration drug AD-NP1 for clinical trials
2025-10-06
Key takeaways
Internal organ tissues often don’t heal after illness or injury and lose some function, such as the heart after a heart attack. UCLA cardiologists have identified a protein that interferes with healing.
Funded entirely by federal and state grants, the researchers developed a drug to block this protein and promote tissue regeneration.
The FDA has now granted approval to begin Phase I clinical trials of the first-in-class drug for tissue repair, called AD-NP1, in humans.
The body’s tissues can get injured in many ways, but while some injuries ...
Exploring the therapeutic potential of cannabidiol for Alzheimer's
2025-10-06
Neuroinflammation damages neurons and can contribute to diseases like Alzheimer’s. Cannabidiol (CBD) has anti-inflammatory properties, which suggests that it could combat neuroinflammation in Alzheimer’s. In a new eNeuro paper, Babak Baban and colleagues, from Augusta University, explored whether CBD can be leveraged as an antiinflammatory treatment in an established Alzheimer’s disease mouse model.
The researchers assessed two distinct mechanisms for shaping immune responses and regulating neuroinflammation ...
We need a solar sail probe to detect space tornadoes earlier, more accurately, U-M researchers say
2025-10-06
Images
Spirals of solar wind can spin off larger solar eruptions and disrupt Earth's magnetic field, yet they are too difficult to detect with our current single-location warning system, according to a new study from the University of Michigan.
But a constellation of spacecraft, including one that sails on sunlight, could help find the tornado-like features in time to protect equipment on Earth and in orbit.
The study results come from computer simulations of a massive cloud of plasma erupting from the sun and moving through the solar system. Because the simulation covers features that span ...
Acute myeloid leukemia (AML): Disease risk but not remission status determines transplant outcomes – new ASAP long-term results
2025-10-06
The selection of patients for allo-HSCT and the best approach to bridging patients to transplantation is continuously discussed by experts. The first results of the ASAP study (ASAP standing for “as soon as possible”), published in 2024, have already attracted considerable attention [2]. ASAP questions existing treatment standards for AML and was the first randomized controlled trial to compare remission induction with salvage chemotherapy prior to allo-HSCT – which represents ...
Sperm microRNAs: Key regulators of the paternal transmission of exercise capacity
2025-10-06
In a recent study published in Cell Metabolism, a collaborative research team led by Chen-Yu Zhang, Xi Chen, and Di-Jun Chen from Nanjing University, together with Tao Zhang from Nanjing Medical University, reported groundbreaking findings in their paper entitled “Paternal exercise confers endurance capacity to offspring through sperm microRNAs.” This research provides the first evidence that sperm microRNAs act as carriers of epigenetic information, enabling the intergenerational transmission of paternal ...
Seeing double: Clever images open doors for brain research
2025-10-06
New artificial intelligence-generated images that appear to be one thing, but something else entirely when rotated, are helping scientists test the human mind.
The work by Johns Hopkins University perception researchers addresses a longstanding need for uniform stimuli to rigorously study how people mentally process visual information.
“These images are really important because we can use them to study all sorts of effects that scientists previously thought were nearly impossible to study in isolation—everything from size to animacy to emotion,” said ...
Inhaler-related greenhouse gas emissions in the US
2025-10-06
About The Study: Inhaler-related emissions in the U.S. have increased over the past decade. Policymakers and regulators seeking to reduce emissions should identify targeted solutions aimed at shifting utilization to currently marketed dry powder and soft mist inhalers while facilitating the entry of newer, affordable metered-dose products containing propellants with low global warming potential.
Corresponding Author: To contact the corresponding author, William B. Feldman, MD, DPhil, MPH, email wfeldman@mednet.ucla.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2025.16524)
Editor’s ...
UCLA Health study finds inhalers for asthma and COPD drive significant greenhouse gas emissions
2025-10-06
Inhalers are the frontline treatment for asthma and COPD, but they come with a steep environmental cost, according to a new UCLA Health study — the largest to date quantifying inhaler-related emissions in the United States.
Researchers found that inhalers have generated over 2 million metric tons of carbon emissions annually over the past decade, equivalent to the emissions of roughly 530,000 gas-powered cars on the road each year.
The study, published in JAMA, analyzed emissions from the three types of inhalers approved for asthma or COPD from 2014 to 2024. It found that metered-dose inhalers were the most ...
A surgical handover system for patient physiology and safety
2025-10-06
About The Study: In this cohort study, implementation of the sickest patients first (SIPS) surgical handover system (introduction, situation, background, assessment, recommendation; prioritize; summarize) was associated with improvements in handover quality, patient physiology, and staff perceptions of safety without prolonging handover meetings.
Corresponding Author: To contact the corresponding author, Jessica M. Ryan, MB, email jessicaryan@rcsi.com.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.38896)
Editor’s ...
Cardiovascular health changes in young adults and risk of later-life cardiovascular disease
2025-10-06
About The Study: In this prospective cohort study of young adults, unfavorable patterns of cardiovascular health (CVH) change through young adulthood were associated with marked elevations in risk for incident cardiovascular disease (CVD). These data suggest that achieving and maintaining high CVH throughout young adulthood through strategies of primordial prevention are important for prevention of later-life CVD.
Corresponding author: To contact the corresponding author, Donald M. Lloyd-Jones, M.D., ...
LAST 30 PRESS RELEASES:
New software tool MARTi fast-tracks identification and response to microbial threats
Rare brain cell may hold the key to preventing schizophrenia symptoms
A new tool to find hidden ‘zombie cells’
New Cleveland Clinic research finds up to 5% of Americans carry genetic mutations associated with cancer risk
Once tadpoles lose lungs, they never get them back
Small group of users drive invasive species awareness on social media
One bad safety review can tank an Airbnb booking — Even among thousands of positive ones, new study finds
Text-based system speeds up hospital discharges to long-term care
California schools are losing tree canopy
How people learn computer programming
Exploring a mechanism of psychedelics
Scientists can now explore mechanisms behind attachment issues
Researchers watched students’ brains as they learned to program
An AI-powered lifestyle intervention vs human coaching in the diabetes prevention program
AI-powered diabetes prevention program shows similar benefits to those led by people
New study may transform diagnosis of Britain’s number one cancer
Stillbirths in the United States
How animals get their spots, and why they are beautifully imperfect
Stillbirths in the U.S. higher than previously reported, often occur with no clinical risk factors
Durability of 2024-2025 COVID-19 vaccines against JN.1 subvariants
Online unsupervised Tai Chi intervention for knee pain and function in people with knee osteoarthritis
A nose for microbes: how hunger tunes the brain
TRF1 protein loss reduces body fat and improves metabolic health in mice without shortening telomeres
JMIR Medical Education invites submissions on bias, diversity, inclusion, and cultural competence in medical education
SwRI receives $9.9 million contract to assess reliability of F-16 landing gear components
Computer scientists build AI tool to spot risky and unenforceable contract terms
Self-affirmations can boost well-being, study finds
New certification helps clinicians advance digital cardiac care
Why earthquakes sometimes still occur in tectonically silent regions
Music therapy during surgery reduces anesthetic use and stress responses
[Press-News.org] AI and the Future of Cancer Research and Cancer Care to headline October 24 gathering of global oncology leaders at the National Press Club: NFCR Global Summit to feature top scientists, entrepreneursEvent spotlights “what’s next” in cancer breakthroughs, entrepreneurship, and patient care, culminating in honoring Dr. Tony Hunter with the 2025 Szent-Györgyi Prize for Progress in Cancer Research